The Hindu Business Line : Ranbaxy inks pact with CD Pharma for dental drug

New Delhi, March 18 Ranbaxy Laboratories Ltd has announced an exclusive in-licensing agreement with CD Pharma India to market the INERSAN brand in India and Nepal. The patented product, a probiotic preparation, is used for the treatment of dental problems.

Commenting on the development, Mr Sanjeev I. Dani, Senior Vice-President and Regional Director Asia & CIS, Ranbaxy, said “In the post-patent era, we are driven by the need to in-license differentiated products and introduction of INERSAN tablets consolidates Ranbaxy’s position in dental segment.”

The drug is specifically used for treating Periodontitis, Gingivitis and Halitosis which are common dental problems. At present, surgical intervention is the most widely used treatment for this problem. Dental practitioners in India currently do not have any specialised prescription product for these conditions, and INERSAN tablets aims to address this need. Ranbaxy will fix the price of the product in India soon.

Mr Kanwaldeep Chadha, Country Manager, CD Pharma India & Director Asia Pacific (VSL Pharmaceuticals Inc), said, “Internationally, INERSAN has shown good clinical results across trials done in oral inflammatory conditions of different etiologies. Clinical trials conducted in India have also given encouraging results. We plan to introduce trial-backed-first-of-it’s-kind probiotic products in the near future.”

Mr Chadha further added, “Probiotics is a new concept in India and is yet to be completely understood. Medical education is needed to create awareness about probiotics. It is critical to understand that any probiotic food or drug has to have a bare minimum quantity of bacteria to be effective.”